These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 3086761)
1. Profiling of endogenous ligand solutes that bind to serum proteins in sera of patients with uremia. Mabuchi H; Nakahashi H Nephron; 1986; 43(2):110-6. PubMed ID: 3086761 [TBL] [Abstract][Full Text] [Related]
2. Effect of hemodialysis on serum concentrations of HPLC-analyzed accumulating solutes in uremia. Schoots AC; Peeters JA; Gerlag PG Nephron; 1989; 53(3):208-17. PubMed ID: 2507950 [TBL] [Abstract][Full Text] [Related]
3. Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum. Mabuchi H; Nakahashi H Ther Drug Monit; 1988; 10(3):261-4. PubMed ID: 3140432 [TBL] [Abstract][Full Text] [Related]
4. Roles of hippurate and indoxyl sulfate in the impaired ligand binding by azotemic plasma. Gulyassy PF; Jarrard E; Stanfel L Adv Exp Med Biol; 1987; 223():55-8. PubMed ID: 3128940 [No Abstract] [Full Text] [Related]
5. A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. Boelaert J; Lynen F; Glorieux G; Eloot S; Van Landschoot M; Waterloos MA; Sandra P; Vanholder R Anal Bioanal Chem; 2013 Feb; 405(6):1937-47. PubMed ID: 23307120 [TBL] [Abstract][Full Text] [Related]
6. Contributions of hippurate, indoxyl sulfate, and o-hydroxyhippurate to impaired ligand binding by plasma in azotemic humans. Gulyassy PF; Jarrard E; Stanfel LA Biochem Pharmacol; 1987 Dec; 36(24):4215-20. PubMed ID: 3120733 [TBL] [Abstract][Full Text] [Related]
7. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis. Deltombe O; Van Biesen W; Glorieux G; Massy Z; Dhondt A; Eloot S Toxins (Basel); 2015 Sep; 7(10):3933-46. PubMed ID: 26426048 [TBL] [Abstract][Full Text] [Related]
8. Isolation and chemical characterization of 2-hydroxybenzoylglycine as a drug binding inhibitor in uremia. Lichtenwalner DM; Suh B; Lichtenwalner MR J Clin Invest; 1983 May; 71(5):1289-96. PubMed ID: 6853715 [TBL] [Abstract][Full Text] [Related]
9. Are the classical markers sufficient to describe uremic solute accumulation in dialyzed patients? Hippurates reconsidered. Schoots AC; Dijkstra JB; Ringoir SM; Vanholder R; Cramers CA Clin Chem; 1988 Jun; 34(6):1022-9. PubMed ID: 3378319 [TBL] [Abstract][Full Text] [Related]
10. The effect of renal transplantation on a major endogenous ligand retained in uremic serum. Mabuchi H; Nakahashi H; Hamajima T; Aikawa I; Oka T Am J Kidney Dis; 1989 Jan; 13(1):49-54. PubMed ID: 2643310 [TBL] [Abstract][Full Text] [Related]
11. Demonstration of 2-hydroxybenzoylglycine as a drug binding inhibitor in newborn infants. Suh B; Wadsworth SJ; Lichtenwalner DM J Clin Invest; 1987 Oct; 80(4):1125-31. PubMed ID: 3654972 [TBL] [Abstract][Full Text] [Related]
12. Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. Calaf R; Cerini C; Génovésio C; Verhaeghe P; Jourde-Chiche N; Bergé-Lefranc D; Gondouin B; Dou L; Morange S; Argilés A; Rathelot P; Dignat-George F; Brunet P; Charpiot P J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2281-6. PubMed ID: 21727042 [TBL] [Abstract][Full Text] [Related]
13. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Fagugli RM; De Smet R; Buoncristiani U; Lameire N; Vanholder R Am J Kidney Dis; 2002 Aug; 40(2):339-47. PubMed ID: 12148107 [TBL] [Abstract][Full Text] [Related]
14. Screening of UV-absorbing solutes in uremic serum by reversed phase HPLC--change of blood levels in different therapies. Schoots AC; Homan HR; Gladdines MM; Cramers CA; de Smet R; Ringoir SM Clin Chim Acta; 1985 Feb; 146(1):37-51. PubMed ID: 3987038 [TBL] [Abstract][Full Text] [Related]
15. HPLC study of uremic fluids related to optical dialysis adequacy monitoring. Lauri K; Tanner R; Jerotskaja J; Luman M; Fridolin I Int J Artif Organs; 2010 Feb; 33(2):96-104. PubMed ID: 20306436 [TBL] [Abstract][Full Text] [Related]
16. Ultraviolet-absorbing organic anions in uremic serum separated by capillary zone electrophoresis, and quantification of hippuric acid. Schoots AC; Verheggen TP; De Vries PM; Everaerts FM Clin Chem; 1990 Mar; 36(3):435-40. PubMed ID: 2311210 [TBL] [Abstract][Full Text] [Related]
17. Correlation of a colorimetric and a HPLC method for the determination of serum hippuric acid concentrations in uremia. Vanholder R; De Smet R; Schoots A; Ringoir S Nephron; 1988; 49(2):164-8. PubMed ID: 3380232 [TBL] [Abstract][Full Text] [Related]
18. Protein binding of ceftriaxone: comparison of three techniques of determination and the effect of 2-hydroxybenzoylglycine, a drug-binding inhibitor in uremia. Fiset C; Vallée F; LeBel M; Bergeron MG Ther Drug Monit; 1986; 8(4):483-9. PubMed ID: 3824437 [TBL] [Abstract][Full Text] [Related]
19. Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients. De Smet R; Vogeleere P; Van Kaer J; Lameire N; Vanholder R J Chromatogr A; 1999 Jun; 847(1-2):141-53. PubMed ID: 10431358 [TBL] [Abstract][Full Text] [Related]
20. Determination of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, a major endogenous ligand substance in uremic serum, by high-performance liquid chromatography with ultraviolet detection. Mabuchi H; Nakahashi H J Chromatogr; 1987 Mar; 415(1):110-7. PubMed ID: 3584344 [No Abstract] [Full Text] [Related] [Next] [New Search]